Showing results (231-240 of 241) with videos related to
Sort By:
Pageof 25
Translational Lung Cancer Research|November 19, 2020
Evaluating the diagnostic accuracy of a ctDNA methylation classifier for incidental lung nodules: protocol for a prospective, observational, and multicenter clinical trial of 10,560 casesWenhua Liang, Dan Liu, Min Li, et al.Plos One|August 22, 2008
Clinical characteristics of 26 human cases of highly pathogenic avian influenza A (H5N1) virus infection in ChinaHongjie Yu, Zhancheng Gao, Zijian Feng, et al.Med (New York, N.Y.)|April 12, 2025
Multidisciplinary expert consensus on diagnosis and treatment of multiple lung cancersKezhong Chen, Anwen Liu, Changli Wang, et al.The Lancet. Oncology|December 9, 2024
Deep learning using histological images for gene mutation prediction in lung cancer: a multicentre retrospective studyYu Zhao, Shan Xiong, Qin Ren, et al.Journal for Immunotherapy of Cancer|November 28, 2024
Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 studyCaicun Zhou, Gongyan Chen, Yunchao Huang, et al.Cancer Communications (London, England)|July 17, 2024
Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS)Shun Lu, Xiaorong Dong, Hong Jian, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 16, 2023
Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 TrialCaicun Zhou, Gongyan Chen, Yunchao Huang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2022
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R MutationsShun Lu, Xiaorong Dong, Hong Jian, et al.Journal of Thoracic Disease|May 22, 2025
Expert consensus on cancer treatment-related lung injuryXinqing Lin, Hui Guo, Wei Zhao, et al.Translational Lung Cancer Research|September 11, 2023
International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary diseaseChengzhi Zhou, Yinyin Qin, Wei Zhao, et al.Pageof 25